New tobacco product alert: Camel Snus is on the loose

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 1
Volume 17
Issue 1

Imagine my surprise to unwrap my Sunday paper one day last month and find inside a clever advertising pamphlet and a card good for a free tin of Camel Snus (pronounced "snoose"), R.J. Reynolds' new flavored spitless chewing tobacco.

Imagine my surprise to unwrap my Sunday paper one day last month and find inside a clever advertising pamphlet and a card good for a free tin of Camel Snus (pronounced "snoose"), R.J. Reynolds' new flavored spitless chewing tobacco. And Reynolds is not alone: Phillip Morris is also testing snus products. Never heard of it? Camel Snus was recently test marketed in Portland, Oregon, and Austin, Texas, and the test has now spread to eight cities.

Camel Snus is a dime-sized pouch of powdered chew tobacco, packaged in tins of 20. The tobacco is pasteurized, not fermented, and the user does not have to spit. That's all we know, since tobacco companies are not required to list the ingredients in their products.

Camel Snus is so "cool" that it is refrigerated "so it's fresh when you buy it," but oddly does not have to be refrigerated once opened. It seems to be a form of snuff (chewed instead of sniffed) and is especially popular in Sweden where it originated. It can be used on airplanes and in other nonsmoking areas, "pleasure for wherever," as the pamphlet says.

The first two test markets-Portland and Austin-are known as hip, young, nonsmoking towns, so it doesn't seem to me that the Camel Snus advertising is aimed at people who already use tobacco, to convince them to switch, but rather at nonsmokers, to get them to start.

This is all so outrageous I could spit (or not)! Your comments are welcome. Please send to: JSkinner@cmp.com.

Recent Videos
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Related Content